NMOSD的真实世界和临床数据, 包括迟到的演讲, will illustrate safety 和 efficacy of Ultomiris 和 Soliris 和 help inform clinical practice
Alexion, 澳门在线赌城娱乐罕见病, 将在MSMilan2023上展示新的数据, the 9th Joint Meeting of the European Committee for Treatment 和 Research in Multiple Sclerosis 和 Americas Committee for Treatment 和 Research in Multiple Sclerosis (ECTRIMS-ACTRIMS), 将于2023年10月11日至13日举行.
Real-world 和 clinical data will provide further evidence to support the established safety 和 efficacy of Ultomiris (ravulizumab)和 Soliris (eculizumab) in treating anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), furthering the Company’s ambition to redefine care for people living with this disease.
克利斯朵夫Hotermans, 高级副总裁, 全球医疗事务主管, Alexion, said: “Our data at MSMilan2023 emphasize the promise of C5 inhibition in NMOSD 和 offer insights to help guide clinical decision-making 和 care. Alexion remains committed to advancing underst和ing of this rare neurological disease, the patient experience 和 the role of our medicines in helping to prevent debilitating relapses.”
Reinforcing the potential of C5 inhibition to transform treatment l和scape for AQP4 Ab+ NMOSD
A late-breaking poster presentation will detail encouraging safety findings for patients with AQP4 Ab+ NMOSD who switched from rituximab to C5 inhibitor therapy in the Phase III CHAMPION-NMOSD 和 PREVENT clinical trials. This post-hoc analysis will show no differences in safety outcomes among patients who used rituximab three to twelve months prior to their first dose of Ultomiris or Soliris 和 provide information to guide clinical decision-making when considering a switch from rituximab to C5 inhibitor therapy.
此外，三年上市后的监测数据 Soliris among Japanese patients has been shortlisted to be qualified for one of the Five Best Poster Awards at the Congress. 研究结果将说明，现实世界的安全性和有效性 Soliris in Japanese patients with AQP4 Ab+ NMOSD are consistent with results from the Phase III PREVENT trial. The results will also show that concomitant immunosuppressive therapy (IST) use decreased over time among patients treated with Soliris，强化…的潜力 Soliris 减轻患者的IST负担.
此外，海报展示将概述长期安全数据 Ultomiris—— 和 Soliris对待病人 from clinical trials 和 post-marketing surveillance across indications, 重点关注脑膜炎球菌感染数据. Results will show meningococcal infection rates 和 infection-related mortality rates remained stable, 即使是接受治疗的病人数量 Soliris 随着时间增长. 此外，结果将表明在 Ultomiris对待病人.
MSMilan2023期间的Alexion演示
第一作者 |
摘要标题 |
展示细节 |
|---|---|---|
Levy,迈克尔 |
Safety findings in patients with AQP4+ NMOSD who received eculizumab or ravulizumab in the PREVENT 和 CHAMPION-NMOSD studies 和 had received rituximab within 1 year prior to enrolment |
海报展示P378 2023年10月11日 16:30-18:30 c |
Nakahara、金 |
Long-term safety 和 effectiveness of eculizumab in patients with AQP4+ neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance |
海报简报P010 2023年10月11日 16:30-18:30 c |
李,贾斯汀 |
Switching from rituximab to eculizumab in patients with AQP4+ NMOSD in the United States: Impact on hospitalisations 和 comorbidities |
海报展示P358 2023年10月11日 16:30-18:30 c |
家人,萨米 |
Meningococcal infections in eculizumab- or ravulizumab- treated patients with neuromyelitis optica spectrum disorder: a clinical 和 real-world pharmacovigilance update across indications |
海报介绍P410 2023年10月12日 17:00-19:00 c |
Papp,维多利亚 |
The socio-economic burden of AQP4-antibody seropositive NMOSD: a national-wide registry-based study* |
海报介绍P490 2023年10月12日 17:00-19:00 c
|
韦弗斯,Alize |
NMOSDCopilot, a software as a medical device for patients with NMOSD: a patient-centred usability study** |
海报展示P1034 ePoster只 |
弗朗西斯,安娜 |
超额死亡率, causes of death 和 last EDSS score prior to death in patients with AQP4 antibody positive neuromyelitis optica spectrum disorder |
海报展示P1018 ePoster只 |
*由Alexion支持的欧登塞大学医院研究
**由Alexion支持的Ad Scientiam研究
笔记
Alexion
Alexion, 澳门在线赌城娱乐罕见病, 澳门在线赌城娱乐内部的团队专注于罕见疾病吗, 在2021年收购Alexion Pharmaceuticals后创建, 公司. 作为罕见病领域三十多年的领导者, Alexion is focused on serving patients 和 families affected by rare diseases 和 devastating conditions through the discovery, 改变生活的药物的开发和商业化. Alexion focuses its research efforts on novel molecules 和 targets in the complement cascade 和 its 发展 efforts on haematology, 肾脏学, 神经学, 代谢紊乱, 心脏病学和眼科. 总部设在波士顿, 麻萨诸塞州, Alexion has offices around the globe 和 serves patients in more than 50 countries.
澳门在线赌城娱乐
澳门在线赌城娱乐(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, 以科学为主导的澳门第一赌城在线娱乐公司，专注于发现, 发展, 以及肿瘤学处方药的商业化, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries 和 its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com 并在社交媒体上关注公司 @澳门在线赌城娱乐.
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.